- Home
- GRI vs SGLY Comparison
GRI vs SGLY Comparison
Compare GRI & SGLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRI
- SGLY
- Stock Information
- Founded
- GRI 2018
- SGLY 2001
- Country
- GRI United States
- SGLY United States
- Employees
- GRI N/A
- SGLY N/A
- Industry
- GRI Biotechnology: Pharmaceutical Preparations
- SGLY
- Sector
- GRI Health Care
- SGLY
- Exchange
- GRI Nasdaq
- SGLY Nasdaq
- Market Cap
- GRI 6.1M
- SGLY 5.8M
- IPO Year
- GRI N/A
- SGLY 2008
- Fundamental
- Price
- GRI $0.78
- SGLY $1.65
- Analyst Decision
- GRI Strong Buy
- SGLY
- Analyst Count
- GRI 2
- SGLY 0
- Target Price
- GRI $11.50
- SGLY N/A
- AVG Volume (30 Days)
- GRI 377.5K
- SGLY 16.1K
- Earning Date
- GRI 11-14-2024
- SGLY 11-14-2024
- Dividend Yield
- GRI N/A
- SGLY N/A
- EPS Growth
- GRI N/A
- SGLY N/A
- EPS
- GRI N/A
- SGLY N/A
- Revenue
- GRI N/A
- SGLY $2,742,157.00
- Revenue This Year
- GRI N/A
- SGLY N/A
- Revenue Next Year
- GRI N/A
- SGLY N/A
- P/E Ratio
- GRI N/A
- SGLY N/A
- Revenue Growth
- GRI N/A
- SGLY N/A
- 52 Week Low
- GRI $0.30
- SGLY $1.27
- 52 Week High
- GRI $65.00
- SGLY $7.65
- Technical
- Relative Strength Index (RSI)
- GRI 49.02
- SGLY 49.34
- Support Level
- GRI $0.75
- SGLY $1.58
- Resistance Level
- GRI $1.00
- SGLY $1.71
- Average True Range (ATR)
- GRI 0.09
- SGLY 0.10
- MACD
- GRI -0.00
- SGLY 0.01
- Stochastic Oscillator
- GRI 38.93
- SGLY 66.65
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
About SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.